GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Instem PLC (LSE:INS) » Definitions » Debt-to-EBITDA

Instem (LSE:INS) Debt-to-EBITDA : 0.49 (As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Instem Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Instem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £1.58 Mil. Instem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.48 Mil. Instem's annualized EBITDA for the quarter that ended in Jun. 2023 was £4.20 Mil. Instem's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 0.49.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Instem's Debt-to-EBITDA or its related term are showing as below:

LSE:INS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02   Med: 0.14   Max: 1.91
Current: 0.25

During the past 13 years, the highest Debt-to-EBITDA Ratio of Instem was 1.91. The lowest was 0.02. And the median was 0.14.

LSE:INS's Debt-to-EBITDA is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 2.58 vs LSE:INS: 0.25

Instem Debt-to-EBITDA Historical Data

The historical data trend for Instem's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instem Debt-to-EBITDA Chart

Instem Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 1.91 0.59 0.30 0.12

Instem Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.25 0.19 0.10 0.49

Competitive Comparison of Instem's Debt-to-EBITDA

For the Health Information Services subindustry, Instem's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instem's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Instem's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Instem's Debt-to-EBITDA falls into.



Instem Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Instem's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.814 + 0.491) / 10.972
=0.12

Instem's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.575 + 0.477) / 4.204
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.


Instem  (LSE:INS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Instem Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Instem's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Instem (LSE:INS) Business Description

Traded in Other Exchanges
N/A
Address
Diamond Way, Stone Business Park, Stone, Staffordshire, GBR, ST15 0SD
Instem PLC acts as a supplier of IT applications and technology-enabled outsourced services to the global health and life sciences community. Its segments include Study Management, Regulatory Solutions, and In Silico Solutions, Clinical Trial Acceleration. The company generates maximum revenue from Study Management. Geographically, it derives a majority of its revenue from the United States and also has a presence in the Europe and Rest of the World. Its portfolio of software solutions includes Instem Cloud, SEND Data Conversion, KnowledgeScan, SENDReady Consulting, Solution Deployment, Validation, Data Management, and Regulatory Information Management.

Instem (LSE:INS) Headlines

No Headlines